Lung function and asthma control with beclomethasone and formoterol in a single inhaler

Respiratory Medicine

Volumn 103, Issue 1, 2009, Pages 41-49

  Huchon, G ^a   Magnussen, H ^b   Chuchalin, A ^c   Dymek, L ^d   Gonod, F Bonnet ^e   Bousquet, J ^f  

^a HÔTEL DIEU   (France)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d Centrum Medyczne Lucyna Andrzej Dymek   (Poland)

^e CHIESI FARMACEUTICI S P A   (Italy)

^f HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Airway inflammation; Combination therapy; Corticosteroid; Extra fine; Hydrofluoroalkane; Long acting 2 agonist

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; CORTICOSTEROID; FORMOTEROL FUMARATE; FOSTER; SALMETEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; HYDROCORTISONE; MALE; METERED DOSE INHALERS; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; TREATMENT OUTCOME;

EID: 58049218972     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.09.002     Document Type: Article

References (28)

1. Bousquet J., Clark T.J., Hurd S., Khaltaev N., Lenfant C., O'Byrne P., et al. GINA guidelines on asthma and beyond. Allergy 62 (2007) 102-112
2. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31 (2008) 143-178
3. Lewis D.A., Ganderton D., Meakin B.J., and Brambilla G. Modulite: a simple solution to a difficult problem. Respiration 72 Suppl. 1 (2005) 3-5
4. Dhillon S., and Keating G.M. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs 66 (2006) 1475-1483
5. Mariotti F., Poli G., Acerbi D., Herpich C., Brand P., and Meyer T. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients. Eur Res Congr (2008) Abstract book: Poster P649
6. Papi A., Paggiaro P., Nicolini G., Vignola A.M., and Fabbri L.M. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 62 (2007) 1182-1188
7. Papi A., Paggiaro P.L., Nicolini G., Vignola A.M., and Fabbri L.M. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 29 (2007) 682-689
8. Sutherland E.R., and Martin R.J. Targeting the distal lung in asthma: do inhaled corticosteroids treat all areas of inflammation?. Treat Respir Med 4 (2005) 223-229
9. Rigamonti E., Kottakis I., Pelc M., Grzelewska-Rzymowska I., and Feschencko Y. Comparison of a new extra-fine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur Respir J 28 Suppl. 50 (2006) 206s
10. Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Vanden Burgt J., et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 104 (1999) 1215-1222
11. Global strategy for asthma management and prevention. Revised 2005 (2005).
12. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 144 (1991) 1202-1218
13. Zetterstrom O., Buhl R., Mellem H., Perpina M., Hedman J., O'Neill S., et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
14. Chrousos G.P., and Harris A.G. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Neuroimmunomodulation 5 (1998) 277-287
15. Aubier M., Pieters W.R., Schlosser N.J., and Steinmetz K.O. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93 (1999) 876-884
16. Chapman K.R., Ringdal N., Backer V., Palmqvist M., Saarelainen S., and Briggs M. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 6 (1999) 45-51
17. Jenkins C., Kolarikova R., Kuna P., Caillaud D., Sanchis J., Popp W., et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 11 (2006) 276-286
18. Van den Berg N.J., Ossip M.S., Hederos C.A., Anttila H., Ribeiro B.L., and Davies P.I. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol 30 (2000) 97-105
19. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 94 (2000) 549-555
20. Gross G., Thompson P.J., Chervinsky P., and Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 115 (1999) 343-351
21. Boulet L.P., Cartier A., Ernst P., Larivee P., and Laviolette M. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months. Can Respir J 11 (2004) 123-130
22. Humbert M., Holgate S., Boulet L.P., and Bousquet J. Asthma control or severity: that is the question. Allergy 62 (2007) 95-101
23. Juniper E.F., O'Byrne P.M., Ferrie P.J., King D.R., and Roberts J.N. Measuring asthma control. Clinic questionnaire or daily diary?. Am J Respir Crit Care Med 162 (2000) 1330-1334
24. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113 (2004) 59-65
25. Nelson H.S., Chapman K.R., Pyke S.D., Johnson M., and Pritchard J.N. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 112 (2003) 29-36
26. Lewis D., Brambilla G., Church T., and Meakin B. Beclomethasone dipropionate and formoterol association within a combination HFA solution MDI. Respir Drug Delivery 3 (2006) 939-942
27. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 19 (2002) 182-191
28. Bousquet J., and Dell'Anna C. Modulite technology in the development of formoterol HFApMDI: clinical evidence and future opportunities. Expert Rev Resp Med 2 1 (2008) 27-36